Table 3.

MRI new lesion activity based on annual scans

Outcome measureTreatment groupResultGroup comparisons
* The approximate 95% confidence intervals were calculated based on median and associated rank.
Median new T2 lesions per patientPlacebo/22 (n = 90)2.0 (1.67, 3.25)Rx22 vs placebo/22: p < 0.001
per scan (95% CI*), years 1–4Placebo/44 (n = 92)2.7 (2.0, 3.5)Rx44 vs placebo/44: p < 0.001
Rx22 (n = 180)1.3 (1.0, 1.75)Rx44 vs Rx22: p < 0.001
Rx44 (n = 180)0.5 (0.33, 0.67)
Median % scans with new T2 lesions (95% CI)Rx22, years 1–4 (n = 166)66.7 (50, 75)Rx44 vs Rx22: p < 0.001
Rx44, years 1–4 (n = 167)33.3 (25, 50)
Placebo/22, years 1–2 (n = 85)100 (100, 100)Placebo/22 year 1–2 vs 3–4: p < 0.001
Placebo/22, years 3–4 (n = 80)50 (50, 100)
Placebo/44, years 1–2 (n = 77)100 (100, 100)Placebo/44 year 1–2 vs 3–4: p < 0.001
Placebo/44, years 3–4 (n = 75)50 (50, 100)
Median new T2 lesions per patientPlacebo/22 (n = 80)0.5 (0.5, 1.0)Rx22 vs placebo/22: p = 0.801
per scan (95% CI), years 3–4Placebo/44 (n = 75)1.0 (0.5, 1.5)Rx44 vs placebo/44: p < 0.001
Rx22 (n = 161)1.0 (0.5, 1.0)Rx44 vs Rx22: p < 0.001
Rx44 (n = 150)0.0 (0.0, 0.0)
Median % scans with new T2Placebo/22 (n = 80)50 (50, 100)Rx22 vs placebo/22: p = 0.790
lesions (95% CI), years 3–4Placebo/44 (n = 75)50 (50, 100)Rx44 vs placebo/44: p < 0.001
Rx22 (n = 161)50 (50, 100)Rx44 vs Rx22: p < 0.001
Rx44 (n = 150)0 (0, 0)